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Abstract
The treatment of human hepatocellular carcinoma (HCC) cell lines with (+)-isocorydine, which was isolated and purified
from Papaveraceae sp. plants, resulted in a growth inhibitory effect caused by the induction of G2/M phase cell cycle arrest
and apoptosis. We report that isocorydine induces G2/M phase arrest by increasing cyclin B1 and p-CDK1 expression levels,
which was caused by decreasing the expression and inhibiting the activation of Cdc25C. The phosphorylation levels of Chk1
and Chk2 were increased after ICD treatment. Furthermore, G2/M arrest induced by ICD can be disrupted by Chk1 siRNA but
not by Chk2 siRNA. In addition, isocorydine treatment led to a decrease in the percentage of CD133
+ PLC/PRF/5 cells.
Interestingly, isocorydine treatment dramatically decreased the tumorigenicity of SMMC-7721 and Huh7 cells. These
findings indicate that isocorydine might be a potential therapeutic drug for the chemotherapeutic treatment of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer in the world [1]. Although many anti-cancer drugs have
been used in the routine clinical treatment of HCC patients and
result in a reduction in tumor volume at early stages, recurrence,
the development of multi-drug resistance, toxicity and side effects
are unfortunately common in patients. Therefore, there is a
pressing need for new therapeutic drugs with increased efficacy
and decreased toxicity.
Cell cycle deregulation is a hallmark of tumor cells, and
targeting the proteins that mediate critical cell cycle processes is an
emerging strategy for the treatment of cancer [2]. The G2/M
checkpoint is the most conspicuous target for many anticancer
drugs [3,4]. CDK1/cyclin B1 and CDK1/cyclin A complexes play
a key role in promoting the G2/M phase transition. Many proteins
are known to regulate the stepwise activation of CDK1, which
controls the G2 to M transition. This process involves additional
proteins, including Weel [5], Myt1 [6], Cdc25C [7] and others.
The phosphatase activity of Cdc25C is inactivated by Chk1/Chk2,
which are activated by ATM/ATR in response to DNA damage.
In the past few years, it has been demonstrated that extracts
from several medicinal plants that are used in traditional medicine
can inhibit tumor proliferation. These plants possess a wide
spectrum of biological activities, including anti-bacterial and
fungicidal properties [8]. Alkaloids from Dicranostigma leptopodum
(Maxim.) Fedde (DLF) possess antipyretic activity and have been
used in the clinical treatment of pulmonary tuberculosis. Whether
these alkaloids also have anti-cancer effects against HCC is poorly
understood. In this study, we demonstrate that components
present in DLF extracts can inhibit the growth of HCC cells by
inducing both G2/M cell cycle arrest and apoptosis. The major
components present in DLF extracts include dicranostigmine,
isocorydine, corydine, protopine and sinoacutine [9]. We found
that L-(+)-isocorydine (ICD) could be isolated and purified from
Papaveraceae sp. plants such as Dactylicapnos scandens Hutchins and
Dicranostigma leptopodum (Maxim.) Fedde. In our pilot study, ICD was
found to play a key role in the anti-proliferative effect observed in
various HCC cell lines. The main goals of the present study were
to demonstrate the anti-cancer effect of purified ICD and to
delineate the underlying mechanisms of its anti-cancer properties.
The chemical structure of ICD is shown in Figure S1.
Results
Dicranostigma Leptopodum (Maxim.) Fedde (DLF)
Extract Suppresses the Proliferation of HCC Cell Lines
through G2/M Arrest
To investigate the suppressive growth effect of the DLF extracts,
the HCC cell lines SMMC-7721, MHCC-97L and Huh7 were
incubated with various concentrations of DLF extracts for 24 and
48 h. Cell proliferation was subsequently measured by the MTT
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36808assay. Our results show that the DLF extracts could inhibit the
growth of all three HCC cell lines in a dose- and time-dependent
manner (Figure 1A, B).
To further elucidate the inhibitory effects of the DLF extracts on
HCC cell growth, the cell cycle distributions of the three cell lines
were determined by flow cytometry. Following treatment with
1 mM thymidine for 24 h to synchronize cells at the G1/S border,
the cells were incubated with 3 mg/ml of DLF extracts for various
times. A dose-dependent G2/M arrest in the cell cycle was
observed in Huh7 and MHCC-97L cells after treatment for 24 h
with DLF extracts. An apoptotic, sub-G0 population of cells was
also observed at the 48 h time point (Figure 1C). We observed that
the accumulation of cells at the G2/M phase could persist for 48 h
(Figure 1D).
We next examined the expression of the key molecules that
promote the G2/M phase transition. Western blot analysis showed
that treatment with the DLF extracts increased the expression of
cyclin B1 and the inhibitory phosphorylation status of CDK1
(Tyr15) in a dose-dependent manner. Because an active CDK1/
cyclin B1 complex is known to promote the transition between the
Figure 1. The effect of DLF on HCC cell growth and cell cycle-related protein expression in vitro. (A, B) Growth inhibition resulting from
the treatment of HCC cells with DLF extracts for 24 h and 48 h. (C) The cell cycle distribution of Huh7 and MHCC-97L cells that were treated with
3 mg/ml DLF for 24 h or 48 h. (D) The percentage of Huh7 cells in G2 phase following treatment with DLF extracts for various times. (E, F) Western
blot analysis of the expression of G2/M phase transition-related proteins after treatment with DLF extracts at various concentrations and for various
times.
doi:10.1371/journal.pone.0036808.g001
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indicated the presence of an inactive complex. The classical
model of the E2F/p-Rb complex suggests that it is the
predominant complex that promotes cell cycle transition. There-
fore, to study the effect of DLF extracts on the E2F1/p-Rb
complex, Western blotting was used to analyze the expression of
E2F1 and p-Rb. The results showed that the DLF extracts did not
affect the phosphorylation status of Rb; however, they did
decrease the expression level of E2F1 (Figure 1E). The p-CDK1
and cyclin B1 levels were maintained for 48 h (Figure 1F), thus
validating the cycle analysis results shown in Figure 1D.
ICD Inhibits Cell Proliferation and Induces Apoptosis
The DLF extracts is a mixture that contains more than five
components [10]. Therefore, to determine which component plays
the major role in suppressing cell growth, we obtained one of the
main components, (+)-Isocorydine (ICD), and investigated its
suppressive effects on tumor cells using the MTT assay.
ICD was found to inhibit the growth of Huh7, SMMC-7721
and PLC/PRF/5 cells in a dose-dependent manner when applied
for 48 h (Figure 2A). To exclude the possibility that cell death was
occurring due to drug toxicity, the effect of ICD on the
immortalized human liver cell line L-02 was also investigated. L-
02 cells were found to have a low sensitivity to ICD treatment and
exhibited an inhibition rate that was less than 1% of that observed
for each of the HCC cell lines at their IC50 values (200, 250 and
300 mg/ml for SMMC-7721, Huh7 and PLC/PRF/5, respective-
ly). The AKT and Erk1/2 pathways are known to play crucial
roles in the promotion of cell survival and the inhibition of
apoptosis; however, ICD did not have any effect on the expression
levels of p-AKT, p-S6 or p-Erk1/2 (Figure S2).
To confirm that ICD treatment induces apoptosis, Huh7 cell
apoptosis was examined using the Annexin V/7-AAD double-
staining method and flow cytometry analysis. Our results revealed
that treatment with ICD at 100, 200 and 300 mg/ml for 48 h
increased the percentage of apoptotic cells to 17.1%, 19.0% and
27.4%, respectively (Figure 2B). We also found that ICD could
induce apoptosis in SMMC-7721 cells (data not shown). An
upregulation of cleaved PARP was detected via Western blotting
in all three HCC cell lines after a 48 h treatment, indicating that
ICD may induce apoptosis through PARP cleavage (Figure 2C).
We used real-time PCR to detect the messenger RNA levels of
several apoptosis-related genes. We observed an upregulation in
the expression of CYP27A1, TNFSRSF10 and TNFSRSF9 after
ICD treatment (Figure S3).
Because ICD was able to inhibit cell proliferation in vitro,w e
next investigated the effects of ICD on HCC tumorigenicity in
vivo using a mouse xenograft model. The body weights of the
ICD-treated groups, which were inoculated with Huh7 or
SMMC-7721 cells, were 23.162.6 g and 27.461.5 g, respec-
tively. No significant difference in body weight was observed
between the inoculated mice and the control mice, which had
body weights of 24.660.5 g (Huh7; p.0.05) and 26.660.8 g
(SMMC-7721; p.0.05), respectively. These results indicate that
ICD does not induce toxicity in mice. The tumor weights of the
xenografts for both ICD and control groups are shown in
Figure 2D and E. Our results indicate that ICD significantly
inhibits the tumorigenicity of Huh7 (p,0.05) and SMMC-7721
(p,0.05) in this model system.
ICD Induces G2/M Cell Cycle Arrest by Decreasing the
Activity of CDK1
To verify that ICD can cause cell cycle arrest, the Huh7 and
SMMC-7721 cell cycles were analyzed following treatment with
ICD at different concentrations and for different times. The
results showed that ICD induced G2/M cell cycle arrest to the
same extent as did the DLF extracts. In the Huh7 cell line, the
percentages of cells in G2/M phase were 6.2%, 32.7%, 51.3%
and 66.2% after an 18 h treatment with ICD concentrations of
0, 200, 300 and 400 mg/ml, respectively (Figure 3A, B). We also
observed cell cycle arrest in SMMC-7721 and Huh7 cells after
ICD treatments of different times and concentrations (summa-
rized in Table 1, 2). In addition, the G2/M phase arrest was
confirmed by Western blotting in Huh7 cells following ICD
treatments of 0, 200, 300 and 400 mg/ml for 18 h (Figure 3C).
ICD treatment led to an upregulation in the expression level of
cyclin B1, but it did not affect the expression level of cyclin A.
Furthermore, ICD treatment led to a decrease in CDK1
activity, as we observed an accumulation of Thr-14/Tyr-15-
phosphorylated (inactive) CDK1. The Cdc25C protein activates
the cyclin B1/CDK1 complex by dephosphorylating these
inhibitory residues on CDK1. We found that ICD treatment
resulted in an increase in the p-Cdc25C protein level and a
decrease in the total level of Cdc25C. Therefore, these data
indicate that ICD may inactivate Cdc25C through an inhibition
of the CDK1/cyclin B1 complex, thereby inducing G2/M
phase arrest. Phosphorylation of CDK1 at Tyr15 and Thr14
sites is known to be performed by the Wee1 and Myt1 protein
kinases. We observed an upregulation in the expression level of
p-Myt1 protein following ICD treatment in Huh7 cells;
however, ICD did not affect the expression level of Wee1.
Similar results were observed in SMMC-7721 and PLC/PRF/5
cells (Figure 3D).
ICD Inactivates Cdc25C by Activating the Chk1/Chk2/
Cdc25C Pathway
It is well known that CDK1/cyclin B1 complex can be
inactivated by the Chk1/Chk2/Cdc25C or p53 pathways.
Therefore, to elucidate which pathway is involved in the
phosphorylation of CDK1 observed in our experiments, we
determined the levels of the phosphorylated forms of these
molecules by Western blotting. Our results indicate that ICD
does not alter the protein level of p53 (either wild type or
mutant), although the p-MDM2 expression level was decreased.
In ICD-treated Huh7 cells, we observed a dose-dependent
upregulation of the phosphorylation of Chk1 (at Ser317, Ser345
and Ser296). ICD also increased the phosphorylation of Chk2
at Thr68, but it had no effect on other phosphorylation sites
within this protein. In PLC/PFR/5 cells, we also observed the
upregulation of p-Chk1 (at Ser345) and p-Chk2 (Thr68) after
ICD treatment (Figure 4A). These results suggest that the
inactivation of CDK1 observed with ICD treatment is mainly
induced by Chk1- and Chk2-mediated phosphorylation.
Because both Chk1 and Chk2 were phosphorylated after ICD
treatment, to further determine the relative contribution of
Chk1 and Chk2 to ICD-induced G2/M arrest, Huh7 cells were
treated with ICD after transfection with either Chk1/Chk2
siRNA or a negative control. The results showed that in the
Chk1 and Chk2 knockdown Huh7 cells, the G2/M percentage
of negative control (NC), Chk1 siRNA and Chk2 siRNA was
47.2%, 0% and 39.0%, respectively, after ICD treatment.
Western blot analysis showed that the expression of p-CDK1
was decreased in the Chk1 knockdown cells compared with the
Chk2 or NC after ICD treatment. The results suggest that
Chk1 siRNA disrupts the G2/M cell cycle arrest, while the
negative control or Chk2 do not.
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+ Fraction and Tumorigenicity
of PLC/PRF/5 CD133
+ Cells
Based on our findings that ICD can inhibit the proliferation of
HCC cell lines in vitro and in vivo, we investigated whether cancer
stem cells (CSCs) were also susceptible. Because CD133 has been
shown to be a cancer stem cell marker in HCC, we examined the
percentage of CD133
+ PLC/PRF/5 cells by flow cytometry after a
48 h ICD treatment. We found that the subpopulation of CD133
+
cells was significantly reduced from 33.8% to 24.9%, 17.4% and
15.1% after treatment with 100, 200 and 300 mg/ml of ICD,
respectively (p,0.05). In addition, we compared the effect of ICD
on the CD133
+ subpopulation with the conventional chemother-
apeutic drug vincristine after treatment for 48 h with a 10 ng/ml
dosage. The results showed that vincristine did not affect the
Figure 2. DLF extracts causes cell growth inhibition and apoptosis. (A) The growth inhibition rates of Huh7, SMMC-7721, PLC/PFR/5 and L-02
cells resulting from treatment with ICD for 48 h. (B) Following the treatment of Huh7 cells with 0, 100, 200 or 300 mg/ml ICD for 48 h, apoptotic cells
were detected by Annexin V and 7-AAD double staining. (C) Western blot analysis of cleaved PARP in Huh7, SMMC-7721 and PLC/PRF/5 cells
following ICD treatment at their respective IC50 values (250 mg/ml, 200 mg/ml, 250 mg/ml). (D) An amount of 1610
6 Huh7 or SMMC-7721 cells/mouse
was subcutaneously injected into nude mice. After 2 weeks, 0.4 mg/ml of ICD or PBS was administered 5 times per week for 4 weeks. The resulting
tumors were excised from the animals after treatment. (E) The tumor weights for the four groups of animals were compared, and statistical
significance was determined using the Student’s t-test. Each point represents the mean 6 SD.
doi:10.1371/journal.pone.0036808.g002
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+ cells (p.0.05) (Figure 5A). ICD also
decreased the percentage of EpCAM
+ cells (EpCAM is another
well-known CSC marker in HCC) (Figure S4).
One of the properties of CSCs is their ability to survive under
anchorage-independent growth conditions. Therefore, the effect of
ICD on hepatosphere formation was determined by the treatment
of PLC/PRF/5 CD133
+/2 subpopulations with ICD or PBS for
48 h. Compared with the PBS control, we found that 150 mg/ml
of ICD remarkably inhibited hepatosphere formation and colony
formation in cells derived from the CD133
+ and CD133
2
subpopulations (Figure 5B, C).
CD133
+ cells are more resistant to routine anti-cancer drugs
compared to CD133
2 fraction. Therefore, the growth inhibitory
effects of CD133
+ and CD133
2 cells induced from ICD treatment
was determined by MTT assay. CD133
+ PLC/PRF/5 cells were
more sensitive to ICD than the CD133
2 cells with time
(Figure 5D).
It is unknown whether ICD can suppress the tumorigenicity of
CD133
+ HCC cells. Therefore, PLC/PRF/5 CD133
+/2 cells
were injected into NOD/SCID mice. Two weeks post-injection,
ICD was administered peritoneally at a dosage of 0.4 mg/mouse 5
times a week for 4 weeks. The results demonstrated that ICD
Figure 3. ICD treatment causes cells cycle arrest at the G2/M phase. (A) The cell cycle distribution of Huh7 cells that were treated with
various doses of ICD for 18 h. (B) A statistical graph of the cell cycle distribution shown in (A). (C and D) Western blot analysis of G2/M transition-
related proteins after ICD treatment of Huh7, SMMC-7721 and PLC/PRF/5 cells for 18 h.
doi:10.1371/journal.pone.0036808.g003
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+ PLC/PRF/5
cells (Figure 5E).
Discussion
DLF (Dicranostigma leptopodum (Maxim.) Fedde) has been used in
the clinical treatment of pulmonary tuberculosis and has been
shown to induce apoptosis in SMMC-7721 human hepatoma cells
[11], an effect that was also observed in the present study;
however, Zhang et al. only determined the effects of the entire DLF
extracts mixture on one human HCC cell line and did not
examine the effects of any DLF alkaloid monomers. Therefore, to
our knowledge, the present study is the first to elucidate the anti-
cancer effects of an alkaloid monomer, ICD, in DLF extracts.
Of the five main components in DLF extracts, only ICD
treatment resulted in an obvious inhibition of proliferation at a
relatively low concentration. Therefore, we focused on the
mechanism behind the anti-tumoral properties of ICD. It has
been reported that ICD can affect the contraction of rabbit
oviduct smooth muscle [12] as well as the action potentials of
isolated canine Purkinje fibers and ventricular muscles [13]. ICD
treatment also imparted relaxant properties on the rat aorta [14].
Additionally, ICD can effectively bind to DNA, thus behaving as a
typical intercalating agent [15].
Table 1. Cell cycle distribution of Huh7 HCC cells after ICD treatment with gradient concentrations.
Time Cell cycle ICD (mg/ml)
0 200 300 400
9h G 1 31.58862.183 12.85060.372 3.48862.232 6.06460.087
S 15.38762.637 32.55963.719 32.58661.917 20.1661.543
G2/M 53.02564.567 54.59063.346 63.925±0.413* 73.775±1.621**
12 h G1 62.84260.780 17.71667.334 15.58261.849 11.19065.711
S 11.70961.287 26.33569.468 19.964.311 17.29466.634
G2/M 25.44862.068 55.948±2.205** 64.517±6.056** 71.515±10.022**
15 h G1 64.10060.307 32.15764.263 24.03162.747 22.27460.003
S 9.52062.065 14.45065.976 14.19561.169 12.54160.996
G2/M 26.37961.759 53.392±2.681** 61.773±3.917** 65.184±0.993**
18 h G1 76.03264.581 45.30262.051 33.03560.882 12.41764.656
S 13.65764.183 3.90561.231 15.93662.302 20.57163.812
G2/M 9.64363.747 50.792±0.843** 51.027±3.184** 67.011±1.949**
Data are mean 6 SD of three independent experiments.
*Significant differences (p,0.05),
**Significant differences (p,0.001).
doi:10.1371/journal.pone.0036808.t001
Table 2. Cell cycle distribution of SMMC-7721 HCC cells after ICD treatment with gradient concentrations.
Time Cell cycle ICD (mg/ml)
0 200 300 400
9h G 1 25.23165.057 15.45160.118 11.86461.171 16.29160.012
S 12.13460.262 12.88961.016 16.75062.054 11.65660.224
G2/M 62.63564.974 71.66±0.898* 71.386±2.936* 72.052±0.235*
12 h G1 83.34860.645 28.34062.718 13.44761.667 4.66960.720
S 5.02160.891 10.94660.572 12.21961.749 27.29460.954
G2/M 11.62961.453 61.102±3.441** 74.332±0.506** 68.036±0.308**
15 h G1 88.42961.526 59.16561.263 15.83660.396 10.78460.114
S 5.87960.708 4.38361.651 11.00562.153 10.36561.636
G2/M 5.68161.734 36.450±0.486** 73.158±2.024** 78.851±1.522**
18 h G1 89.39062.546 78.29860.123 17.41860.554 11.12460.096
S 5.89962.133 2.26360.370 14.19460.882 12.38160.897
G2/M 4.70961.823 19.438±0.480** 68.388±0.327** 76.494±0.800**
Data are mean 6 SD of three independent experiments.
*Significant differences (p,0.05),
**Significant differences (p,0.001).
doi:10.1371/journal.pone.0036808.t002
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IC50 of 200,300 mg/ml. By contrast, L-02 cells were found to
be remarkably resistant to this compound. In L-02 cells, the
observed inhibitory rate was less than 1% at such doses,
indicating that ICD may be less toxic to normal cells than to
cancer cells. Therefore, ICD may not exhibit toxicity in
experimental animals. The AKT pathway has profound effects
on cell proliferation, and the inhibition of this pathway is
beneficial in the treatment of cancer [16,17]. In the present
study, ICD treatment did not alter the expression or the
phosphorylation levels of AKT, S6 or Erk1/2, suggesting that
the observed inhibition of proliferation may not occur via these
pathways.
Many anti-cancer drugs cause cell death through the
induction of apoptosis [18]. Early in the apoptotic process,
phosphatidylserine (PS) becomes exposed on the cell surface.
This event is thought to be important for the ability of
macrophages to recognize apoptotic cells. PARP, which helps to
maintain cell viability, is one of the main cleavage targets of
caspase-3. The cleavage of PARP facilitates cellular disassembly
and is a useful marker for cell apoptosis [19,20]. The apoptosis
evoked by ICD was confirmed by the Annexin V/7-AAD
double-staining method as well as through the examination of
cleaved PARP levels. Here, ICD increased the number of
Annexin V-positive cells and led to an upregulation of cleaved
PARP levels. Because ICD suppressed cell growth and induced
apoptosis in HCC cell lines, we hypothesized that it might
inhibit HCC tumorigenicity in vivo. In our mouse xenograft
study, ICD significantly reduced the tumor volume without
significantly affecting body weight.
The G2/M checkpoint allows the cell to repair DNA damage
before entering mitosis. The stepwise activation of CDK1 is
essential for cells to correctly enter the M phase [21]. This process
involves the formation of a complex between CDK1 and cyclin B1
or cyclin A. CDK1 is subsequently activated via a Cdk-activating
enzyme, which phosphorylates the activating residues on CDK1.
Inhibitory phosphorylation can also be performed at Thr160/161,
Thr14 and Tyr15 by Wee1 [5] and Myt1 [6]. The phosphatase
Cdc25C, by contrast, can dephosphorylate Thr14 and Tyr15 [22].
Cdc25C itself can be inactivated by the Chk1 kinase, which
phosphorylates Ser216 on Cdc25C. Chk2 subsequently binds to
members of the 14-3-3 protein family, resulting in the sequestra-
tion of Cdc25C in the cytoplasm and the prevention of premature
mitosis. The activation of CDK1/cyclin B1 can also be prevented
by p53 [23]. According to our results, ICD treatment induced a
pronounced G2/M phase arrest by increasing the level of cyclin
B1 as well as the accumulation of Thr14/Tyr15-phosphorylated
CDK1. The expression level of cyclin A was not influenced by
ICD treatment. The increased level of the inactive CDK1/cyclin
B1 complex resulted in the decreased expression of E2F1 and,
thus, an inhibition of its function. ICD treatment also led to an
upregulation of Wee1, Myt1 and Ser216-phosphorylated Cdc25C
(Ser216) levels. Our studies therefore suggest that ICD inactivates
the CDK1/cyclin B1 complex by inactivating Cdc25C. This
results in the downregulation of E2F1 expression and G2/M
arrest.
The Chk1/Chk2 proteins participate in the transition
between the G2 and M phases and are potential targets for
cancer therapy [24,25]. These kinases are activated upon DNA
damage, which results in the inactivation of Cdc25C. Chk1 is
activated by phosphorylation at Ser317, Ser345 and Ser296,
Figure 4. The relative contributions of the Chk1, Chk2 and p53 pathways. (A) Western blot analysis of the activation of p53, MDM2, Chk1
and Chk2 in Huh7 and PLC/PFR/5 cells after ICD treatment for 48 h. (B) The cell cycle distribution of Huh7 cells after ICD treatment for 18 h following
siRNA transfection. (C) Western blot analysis of the silencing effect of Chk1 or Chk2 expression levels after transfection with their corresponding
siRNA. (D) Western blot analysis of p-CDK1 or CDK1 expression levels after ICD treatment for 18 h following transfection with their corresponding
siRNA.
doi:10.1371/journal.pone.0036808.g004
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36808Figure 5. The effect of growth suppression on CD133
+/2 PLC/PRF/5. (A) PLC/PRF/5 cells were treated with various doses of ICD or 10 ng/ml
vincristine for 48 h. The percentage of CD133
+ cells was then determined by flow cytometry. Statistically significant differences were determined
using the Student’s t-test (*=p,0.05; each point represents the mean 6 SD). (B) The hepatosphere formation of PLC/PFR/5 CD133
+/2 cells that were
sorted by FACS and treated with PBS or 150 mg/ml of ICD for 48 h. (C) The colony formation of PLC/PRF/5 CD133
+/2 cells that were sorted by FACS
and then treated with PBS or 150 g/ml ICD for 48 h. (D) The growth inhibition rates of PLC/PFR/5 CD133
+/2 cells resulting from 48 and 72 h ICD
treatments. (E and F) An amount of 5000 PLC/PFR/5 CD133
+/2 cells/mouse were subcutaneously injected into nude mice. After 2 weeks, 0.4 mg/ml of
ICD or PBS was administered 5 times per week for 4 weeks. The resulting tumors were excised from the animals after treatment. Statistical
significance was determined using the Student’s t-test. Each point represents the mean 6 SD.
doi:10.1371/journal.pone.0036808.g005
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[26]. In our current study, p-Chk1 (Ser317, Ser345 and Ser296)
and p-Chk2 (Thr68) were upregulated after ICD treatment. To
determine the relative contributions of these proteins on the
ICD-induced cell cycle arrest, we analyzed the cell cycle
distribution of siRNA-mediated Chk1 or Chk2 knockdown
Huh7 cells after treatment with ICD or PBS. The results
showed that Chk1 knockdown disrupts the G2/M arrest
compared with NC or Chk2. These results indicate that ICD
treatment activates Chk1 and Chk2, allowing these kinases to
inactivate Cdc25C. Cdc25C, Wee1 and Myt1 then decrease the
activity of the CDK1/cyclin B1 complex, resulting in an arrest
of the cell cycle at the G2/M phase.
Although many drugs that block cell cycle processes can
inhibit cancer cell growth effectively, they may be more efficient
when combined with clinical chemotherapeutic drugs. Stern et
al. have reported that methionine-depletion induced S/G2 cell
cycle blockage in cancer cells increased the sensitivity to
doxorubicin and vincristine [27]. Therefore, ICD may also
increase the efficiency of routine drugs, although further study is
required to prove this. According to our results, ICD induces
the G2/M phase arrest by activating the Chk1/Cdc25C/CDK1
pathway. However, methionine depletion-induced S/G2 block-
age occurs via a different mechanism than that of ICD. Due to
the central role of DNA methylation to carcinogenesis, cancer
cells are more dependent on methionine than normal cells and
the growth arrest effect by disrupting methionine metabolism is
reversible [28,29]. This suggests that due to their different
mechanisms of blocking the cell cycle, there may be synergistic
effects when combining ICD with methionine-depletion to treat
tumors.
Cancer stem cells are a small population of cells within a tumor
that are thought to drive tumor growth and recurrence [30]. They
are capable of self-renewal and show chemoresistance to many
current cancer chemotherapeutic drugs [31]. CSCs, which cannot
be eliminated by conventional medications, survive to regenerate
new tumors [32]. Recently, HCC CSCs have been identified by
several markers, such as CD133 [33] and epithelial cell adhesion
molecule (EpCAM) [34].
In our present study, we showed that ICD can significantly
decrease the percentage of CD133
+ cells, while vincristine was
unable to do so. We also used salnomycin, which was reported
to selectively kill CSCs in breast cancer [35], as another positive
control. We found that salnomycin decreased the percentage of
CD133
+ cells, but to a lesser extent than ICD at the same
concentration. In addition, ICD can also decrease the percent-
age of cells expressing EpCAM, which is another CSC marker.
CSCs are unique in their ability to form hepatospheres under
anchorage-independent growth conditions as well as to form
colonies [36]. We found that ICD could decrease the ability of
PLC/PRF/5 CD133
+ cells to form hepatospheres as well as
their ability to form colonies. CD133
+ cells are more resistant to
conventional drugs such as doxorubicin [31]. In our study, ICD
exerted a relatively stronger inhibitory impact on CD133
+ cells
compared with CD133
- cells. Furthermore, ICD could remark-
ably reduce the tumorigenicity of CD133
+ cells. Further study is
required to ascertain the underlying mechanism of the ICD-
dependent decrease in the fraction and tumorigenicity of
CD133
+ cells.
In summary, ICD inhibits proliferation in HCC cell lines by
inducing a G2/M arrest and subsequent apoptosis. ICD also
decreases the tumor volume of xenografts without any adverse
effects on body weight in nude mice and NOD/SCID mice. In
addition, ICD can decrease the percentage of CD133
+ cells as well
as reduce their ability to form tumor-like spheres in vitro. These
results indicate that ICD might be therapeutically useful in the
treatment of HCC.
Materials and Methods
Cell Lines and Cell Culture
The human HCC cell lines SMMC-7721 and Huh7 were
provided by the Cell Bank of the Institute of Biochemistry and Cell
Biology at the China Academy of Sciences (Shanghai, China).
MHCC-97L was obtained from the Liver Cancer Institute of
Zhongshan Hospital at Fudan University (Shanghai, China).
PLC/PRF/5 and SNU-182 were purchased from the American
Type Culture Collection (ATCC) (Manassas, USA). All cell lines
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Sigma-Aldrich, St Louis, MO) containing 10% heat-inactivated
fetal bovine serum (FBS) (Hyclone, Logan, UT) and supplemented
with 100 IU/ml penicillin G and 100 mg/ml streptomycin
(Sigma). All cell lines were incubated at 37uC in a humidified
atmosphere with 5% CO2.
Drug Stocks
The Dicranostigma leptopodum (Maxim) Fedde (DLF) alkaloid extract
was prepared at a stock concentration of 50 mg/ml in PBS and
stored in the dark at 4uC. Isocorydine (ICD), isolated from
Dactylicapnos scandens Hutchins (Shanghai Zhanshu Chemical Sci-
Tech Company, China), was diluted at 10 mg/ml in PBS and
stored at 4uC in a dark bottle.
Fluorescence-Activated Cell Sorting (FACS)
The PLC/PFR/5 cells were incubated with a PE-conjugated
CD133/1(AC133) antibody (Miltenyi Biotec, Germany) and
sorted into CD133
+ and CD133
2 cell subpopulations on an Epics
Altra flow cytometer (Beckman Coulter, USA). The purity of the
sorted cells was evaluated by Western blotting.
Cell Cycle Analysis
For cell cycle analysis, 2610
5 cells were plated in a 6-well
culture plate and grown for 24 h. The cells were then incubated
with 1 mM thymidine (Sigma-Aldrich) for 24 h to synchronize
cells at the G1/S boundary. The cells were then treated with fresh
media containing various concentrations of ICD for different
times. Next, the cells were trypsinized, washed twice with cold PBS
and fixed with cold 70% ethanol at 220uC overnight. The cells
were then washed twice with PBS and incubated with 10 mg/ml
RNase A, 400 mg/ml propidium iodide and 0.1% Triton X in
PBS at room temperature (RT) for 30 m. Cells were subsequently
analyzed by flow cytometry.
Apoptotic Assay
Annexin V and 7-AAD staining was used to visualize apoptotic
cells according to the manufacturer’s instructions. Briefly, 2610
5
cells were seeded in 6-well plates and treated with ICD at a
concentration of 100, 200 or 300 mg/ml for 48 h. Cells were then
collected and washed twice with PBS and resuspended in 400 mlo f
16binding buffer. Next, 5 ml of the Annexin V-PE and 7-AAD
solution was added, and samples were incubated for 15 m at RT
and analyzed by flow cytometry.
Western Bblotting
Freshly sorted cells were lysed and subjected to sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
electroblotting to nitrocellulose or polyvinylidene difluoride
Isocorydine Inhibits Cell Growth in HCC
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e36808(PVDF) membranes. Proteins on the membranes were immuno-
detected with various specific primary antibodies and HRP-
conjugated secondary antibodies (Table S1). Chemiluminescent
detection was performed by the Supersignal West Femto
Chemiluminescent substrate kit (Thermo scientific, Cat
No. 34095). b-actin was used as a loading control.
Hepatosphere Formation Assay
PLC/PRF/5 CD133
+/2 cells that had been sorted by FACS
were treated with 150 mg/ml of ICD for 48 h and were then
dissociated into single cells. Cells were cultured in suspension in
ultra-low-adherence multiwell plates (Costar) with serum-free
medium. Half of the media volume was changed every other
day for a total of 7 days. Hepatospheres were then counted.
MTT Assay
Cell toxicity and proliferation after ICD treatment were
determined using the MTT assay according to the manufacturer’s
specifications. Briefly, 5000 cells/well were plated in triplicate in
96-well plates, and the cells were exposed to an ICD concentration
gradient for 24, 48 and 72 h. The MTT reagent was prepared at
5 mg/ml in PBS. This MTT stock solution was then added to
each well at a 1:10 dilution. Cells were incubated for 4 h.
Afterward, the resulting crystals were dissolved in 100 ml DMSO,
and the absorbance at 570 nm was measured using an ELISA
plate reader, with background subtraction measurements per-
formed at 630 nm. The inhibition rate was calculated as follows:
Inhibition rate=12(A570–A630) of treated cells/(A570–A630)o f
control cells.
RNA Interference-based Gene Knockdown Experiment
Small-interfering RNA (siRNA) oligos for Chk1, Chk2 and
general negative control were synthesized and annealed by
GenePharma (Shanghai, China). The fragments were designed
to target Chk1 or Chk2 transcripts.
Chk1: 59-GACUGGGACUUGGUGCAAAtt-39 (sense).
59-UUUGCACCAAGUCCCAGUCtt-39 (antisense).
Chk2: 59-GUAAGAAAGUAGCCAUAAATT-39 (sense).
59-UUUAUGGCUACUUUCUUACTT-39 (antisense).
In vivo Tumorigenicity
The tumor suppressive effect of ICD on Huh7 and SMMC-
7721 xenografts in vivo was determined by subcutaneously injecting
1610
6 cells into 6- to 8-week-old male nude mice. Two weeks after
the cells were injected, 0.4 mg/mouse ICD or PBS control
injections were administered intraperitoneally 5 times per week for
4 weeks. To evaluate the effect of ICD on the tumorigenicity of
CD133
+/2 HCC cells, 6- to 8-week-old male NOD/SCID mice,
maintained under standard conditions according to institutional
guidelines, were subcutaneously inoculated bilaterally with 5000
sorted CD133
+ or CD133
2 PLC/PRF/5 cells in 50 ml of a serum-
free DMEM/Matrigel mixture (1:1) (BD Biosciences). Two weeks
later, the mice were injected intraperitoneally with ICD at a dose
of 0.4 mg/mouse 5 times per week for 4 weeks. The effect of ICD
treatment on tumor growth was evaluated by weighing the tumor
masses and subsequent statistical analysis.
All of the animals used in this study were manipulated and
housed according to protocols approved by the Shanghai Medical
Experimental Animal Care Commission.
Statistical Analysis
All of the data are presented as the mean 6 standard deviation
(SD). Statistical analyses (two group comparisons) were performed
using the Student’s t-test. p,0.05 was considered to be statistically
significant.
Supporting Information
Figure S1 The chemical structure of ICD.
(TIF)
Figure S2 Western blot analysis of AKT, p-AKT, S6, p-
S6, Erk1/2 and p-Erk1/2 in Huh7, SMMC-7721 and
PLC/PRF/5 cell lines after treatment with ICD at a
concentration of 250, 200 or 250 mg/ml for 48 h.
(TIF)
Figure S3 The apoptosis-related genes of Huh7, SMMC-
7721 and PLC/PRF/5 cell lines after ICD treatment for
48 h evaluated using real-time PCR.
(TIF)
Figure S4 The percentage of EpCAM expression in
Huh7 and SNU-182 cells treated with 200, 300 and
400 mg/ml of ICD for 48 h. Statistically significant differences
were determined using a Student’s t- test (*=p,0.05,
**=p,0.001, each point represents the mean 6 SD).
(TIF)
Table S1 Antibodies used in this study.
(DOC)
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